Achieving complete remission in CLL patients treated with ibrutinib: Clinical significance and predictive factors

Paolo Strati; Ellen J. Schlette; Luisa M. Solis Soto; Daniela E. Duenas; Mariela Sivina; Ekaterina Kim; Michael J. Keating; William G. Wierda; Alessandra Ferrajoli; Hagop Kantarjian; Zeev Estrov; Nitin Jain; Philip A Thompson; Ignacio I. Wistuba; Jan A. Burger

doi:10.1182/blood.2019003570

Achieving complete remission in CLL patients treated with ibrutinib: Clinical significance and predictive factors

Paolo Strati, Ellen J. Schlette, Luisa M. Solis Soto, Daniela E. Duenas, Mariela Sivina, Ekaterina Kim, Michael J. Keating, William G. Wierda, Alessandra Ferrajoli, Hagop Kantarjian, Zeev Estrov, Nitin Jain, Philip A Thompson, Ignacio I. Wistuba, Jan A. Burger

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Original language	English (US)
Pages (from-to)	510-513
Number of pages	4
Journal	Blood
Volume	135
Issue number	7
DOIs	https://doi.org/10.1182/blood.2019003570
State	Published - Feb 13 2020

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood.2019003570

Cite this

Strati, P., Schlette, E. J., Solis Soto, L. M., Duenas, D. E., Sivina, M., Kim, E., Keating, M. J., Wierda, W. G., Ferrajoli, A., Kantarjian, H., Estrov, Z., Jain, N., Thompson, P. A., Wistuba, I. I., & Burger, J. A. (2020). Achieving complete remission in CLL patients treated with ibrutinib: Clinical significance and predictive factors. Blood, 135(7), 510-513. https://doi.org/10.1182/blood.2019003570

Strati, P , Schlette, EJ , Solis Soto, LM , Duenas, DE , Sivina, M , Kim, E, Keating, MJ, Wierda, WG , Ferrajoli, A , Kantarjian, H, Estrov, Z, Jain, N, Thompson, PA, Wistuba, II & Burger, JA 2020, 'Achieving complete remission in CLL patients treated with ibrutinib: Clinical significance and predictive factors', Blood, vol. 135, no. 7, pp. 510-513. https://doi.org/10.1182/blood.2019003570

@article{eec797df14bc4cc3b57b030856a125ff,

title = "Achieving complete remission in CLL patients treated with ibrutinib: Clinical significance and predictive factors",

author = "Paolo Strati and Schlette, {Ellen J.} and {Solis Soto}, {Luisa M.} and Duenas, {Daniela E.} and Mariela Sivina and Ekaterina Kim and Keating, {Michael J.} and Wierda, {William G.} and Alessandra Ferrajoli and Hagop Kantarjian and Zeev Estrov and Nitin Jain and Thompson, {Philip A} and Wistuba, {Ignacio I.} and Burger, {Jan A.}",

note = "Funding Information: This work was supported in part by a National Institutes of Health (NIH)/ National Cancer Institute (NCI) support grant (CA016672) to the MD Anderson Cancer Center and by the Conquer Cancer Foundation/ASCO Young Investigator Award. Funding Information: Conflict-of-interest disclosure: J.A.B. and N.J. have received research funding from Pharmacyclics and are consultants for Janssen Pharmaceuticals. N.J. and P.A.T. have served as consultants for AbbVie and Pharmacyclics. The remaining authors declare no competing financial interests.",

year = "2020",

month = feb,

day = "13",

doi = "10.1182/blood.2019003570",

language = "English (US)",

volume = "135",

pages = "510--513",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "7",

}

TY - JOUR

T1 - Achieving complete remission in CLL patients treated with ibrutinib

T2 - Clinical significance and predictive factors

AU - Strati, Paolo

AU - Schlette, Ellen J.

AU - Solis Soto, Luisa M.

AU - Duenas, Daniela E.

AU - Sivina, Mariela

AU - Kim, Ekaterina

AU - Keating, Michael J.

AU - Wierda, William G.

AU - Ferrajoli, Alessandra

AU - Kantarjian, Hagop

AU - Estrov, Zeev

AU - Jain, Nitin

AU - Thompson, Philip A

AU - Wistuba, Ignacio I.

AU - Burger, Jan A.

N1 - Funding Information: This work was supported in part by a National Institutes of Health (NIH)/ National Cancer Institute (NCI) support grant (CA016672) to the MD Anderson Cancer Center and by the Conquer Cancer Foundation/ASCO Young Investigator Award. Funding Information: Conflict-of-interest disclosure: J.A.B. and N.J. have received research funding from Pharmacyclics and are consultants for Janssen Pharmaceuticals. N.J. and P.A.T. have served as consultants for AbbVie and Pharmacyclics. The remaining authors declare no competing financial interests.

PY - 2020/2/13

Y1 - 2020/2/13

UR - http://www.scopus.com/inward/record.url?scp=85079594047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079594047&partnerID=8YFLogxK

U2 - 10.1182/blood.2019003570

DO - 10.1182/blood.2019003570

M3 - Letter

C2 - 31895947

AN - SCOPUS:85079594047

SN - 0006-4971

VL - 135

SP - 510

EP - 513

JO - Blood

JF - Blood

IS - 7

ER -

Achieving complete remission in CLL patients treated with ibrutinib: Clinical significance and predictive factors

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this